Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Without the insulating sheath called myelin, the nervous system would cease to function. Learn about myelin and the lightning…
Appointments are often quick and can be disorienting. Go in with a plan and some strategies and you’ll leave with more of you…
The European Federation of Pharmaceutical Industries and Associations gives its members valuable insights and the opportunity…
Joint problems may be a variable affecting emotional health and quality of life, new study suggests.
Clinical Trials Day Is May 20. Follow the journey of a potential treatment through four important phases.
In addition to its own direct emissions, CSL plans to reduce indirect emissions created by suppliers.
Sessions in June will prepare young rare disease advocates to speak with members of the U.S. Congress.
Clinical trial participants should mirror the population, but minorities are underrepresented.
New research in the journal Clinical and Applied Thrombosis/Hemostasis followed 50 patients post-op.
Americas
Asia Pacific
Middle East
Europe